Skip to content

Use of Percutaneous Ultrasound-Guided Microwave for uterine fibroids treatment

Phase I Clinical Study of Safety and Tolerability of Percutaneous Ultrasound-Guided Microwave for Thermal Ablation of Uterine Myomas. MiWaMA Project (MicroWave Myoma Ablation)

Status
Recruiting
Phases
Phase 1
Study type
Interventional
Source
REBEC
Registry ID
RBR-54jvjfk
Enrollment
Unknown
Registered
2025-08-10
Start date
2024-12-11
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Uterine fibroids

Interventions

A phase I, single-center clinical study was carried out in a hospital in southeastern Brazil, in which 20 women with uterine fibroids will be screened and trated with one session of microwave ablation

Sponsors

Fundação do ABC
Lead Sponsor
Fundação do ABC
Collaborator

Eligibility

Sex/Gender
Female
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Women; 18 of more years old; clinical diagnosis of uterine fibroids from type 2 to type 6, including classification of International Federation of Gynecology and Obstetrics 2-5; with a uterine volume above 50 mL; who report that they will not attempt pregnancy in the next 24 months at the beginning of the study; who have not undergone changes in their clinical conditions through conservative treatments or therapies; without signs of perimenopause; who have a safe transabdominal puncture course available; who report a desire to preserve the uterus; and who have voluntarily accepted microwave ablation treatment, by signing the informed consent form

Exclusion criteria

Exclusion criteria: Women who express a desire to stop participating in the study during the course of treatment; who become pregnant after the procedure; or who have clinically significant adenomyosis; women who have any malignancy in the genital organs,endometriosis requiring surgical treatment; other systemic diseases such as liver, kidney, or heart disease

Design outcomes

Primary

MeasureTime frame
To evaluate differences in fibroid volume before and after treatment

Secondary

MeasureTime frame
To evaluate differences in quality of life before and after treatment;To assess changes in participants' pain before and after treatment

Countries

Brazil

Contacts

Public ContactMichel Zelaquett

Myoma Academy

mzelaquett@inspectto.com.br+55(21)981528556

Outcome results

None listed

Source: REBEC (via WHO ICTRP)